* Conmed Corp CNMD.N CNMD.K is expected to show a rise
in
quarterly revenue when it reports results on April 24 for the
period ending March 31 2024
* The Largo Florida-based company is expected to report a
3.8% increase in revenue to $306.776 million from $295.47
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Conmed Corp is for
earnings of
74 cents per share. The company's EPS guidance on January 31
2024, for the period ended March 31, was between $0.72 and
$0.75
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Conmed Corp
is
$105.00, above its last closing price of $72.61.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 1.11 1.11 1.06 Missed -4.5
Sep. 30 2023 0.83 0.83 0.90 Beat 8.4
Jun. 30 2023 0.79 0.79 0.83 Beat 4.5
Mar. 31 2023 0.60 0.60 0.66 Beat 10.3
Dec. 0.89 0.90 0.42 Missed -53.5
31 2022
Sep. 30 2022 0.75 0.75 0.77 Beat 2.4
Jun. 30 2022 0.74 0.75 0.76 Beat 1.8
Mar. 31 2022 0.62 0.62 0.70 Beat 13.3
This summary was machine generated April 22 at 21:57 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)